Berenberg Bank Has Lowered Expectations for Smith & Nephew (LON:SN) Stock Price

Smith & Nephew (LON:SN) had its target price lowered by equities researchers at Berenberg Bank from GBX 1,300 to GBX 1,250 in a report issued on Friday,London Stock Exchange reports. The firm presently has a “hold” rating on the stock. Berenberg Bank’s price target would suggest a potential upside of 13.07% from the company’s current price.

SN has been the topic of several other reports. Shore Capital Group reiterated a “buy” rating and issued a GBX 1,000 price target on shares of Smith & Nephew in a research report on Tuesday, July 21st. UBS Group reaffirmed a “neutral” rating and issued a GBX 1,300 target price on shares of Smith & Nephew in a research note on Tuesday, May 5th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a GBX 1,400 target price on shares of Smith & Nephew in a report on Thursday, July 30th. Royal Bank Of Canada dropped their price target on Smith & Nephew from GBX 1,350 to GBX 1,250 and set a “sector perform” rating for the company in a research report on Thursday, August 6th. Finally, JPMorgan Chase & Co. cut their price target on Smith & Nephew from GBX 1,438 to GBX 1,290 and set a “neutral” rating for the company in a report on Thursday, August 6th. Three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, Smith & Nephew presently has a consensus rating of “Hold” and a consensus price target of GBX 1,310.

Smith & Nephew Trading Up 1.1%

LON:SN opened at GBX 1,105.50 on Friday. The company has a debt-to-equity ratio of 73.07, a current ratio of 2.14 and a quick ratio of 0.84. The stock has a market cap of £12.12 billion, a P/E ratio of 39.80, a P/E/G ratio of 0.46 and a beta of 0.69. The company’s fifty day simple moving average is GBX 1,135.64 and its 200-day simple moving average is GBX 1,189.09.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.